Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Lupus Nephritis Guidelines in Progress

Alexandra Schultz  |  Issue: April 2011  |  April 13, 2011

According to Dr. Hahn, when the voting was tallied, some areas of the expert opinions did not coincide with current textbook information in how to treat lupus nephritis. New scenarios were therefore constructed to clarify the clinical situation. “You find that, with this method, there are some answers that don’t seem to be in line with current practice, and therefore it is likely that people voting did not interpret the scenario in the same way,” Dr. Hahn notes. “Part of the process is to look where there is a lot of discrepancy in people’s opinions. There were different interpretations of scenarios between experts, so we reconstructed [these hypothetical situations].”

Participating doctors were chosen based on their expertise with writing guidelines, their experience with leading large major clinical trials, or a combination of both. Most of the nephrologists chosen to work alongside their ACR counterparts “have worked on U.S. guidelines of nephrology before,” according to Dr. Hahn.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Hahn also says that one limitation to the guidelines will be the range of products reviewed, because only those products that have gone through high-quality clinical trials in the United States will be seriously considered: “Likely there will be more products released over the next two to three years for management of lupus nephritis … they will be addressed, but we don’t know what will be successful and what won’t be … all we can do is spend a brief time discussing these interesting products.” Dr. Hahn cites belimumab (Benlysta) as an example. Benlysta was recently approved for the treatment of lupus, but its utility in the treatment of lupus nephritis has yet to be studied.

The expected impact of these guidelines is substantial for the rheumatologist in clinical practice. “I think that for clinicians who don’t see many patients with lupus nephritis, it will be helpful because it will be an update on the state of the art,” Dr. Hahn says. “For clinicians quite experienced with lupus nephritis, they will most likely be doing things the way they are recommended anyway … hopefully it will confirm what [they] are already doing.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Alexandra Schultz is a writer based in New Jersey.

Page: 1 2 | Single Page
Share: 

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:AC&RDiagnosisGuidelinesLupus nephritisrheumatologistTreatment

Related Articles

    Lupus Classification Criteria Expanded; Treat-to-Target Approach Gains Support

    July 1, 2014

    Rheumatologists at the California Rheumatology Alliance 10th Annual Medical & Scientific Meeting in San Francisco outline disease classification criteria, treat-to-target approach to lupus

    Combining Humanities, Clinical Care Essential to Providing Quality Healthcare

    February 15, 2017

    WASHINGTON, D.C.—Paulette Hahn, MD, associate professor of medicine specializing in rheumatology at the University of Florida (UF), said she once treated a patient named Monica, a UF undergraduate who had severe inflammatory muscle disease and severe lung disease. The patient’s disease was under control for the time being, but Monica knew she could take a…

    ACR Issues Guidelines, Recommendations for Lupus Nephritis, RA

    June 10, 2012

    Detailed screening and treatment recommendations based on current evidence, extensive literature review.

    Tacrolimus Use for Lupus Nephritis Raises Debate over Role in North American Population

    October 10, 2016

    The following summary regarding use of tacrolimus (TAC) in lupus nephritis highlights a number of debatable points. Although the role of TAC in lupus nephritis remains unproved for North American populations, it might be an excellent option in some clinical situations. These situations include lupus flare during pregnancy and also for lupus nephritis when the…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences